// App-Quantinova.ai

: Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Researchers

Presenter

  • Mark Blaine Geyer

Principal Investigators

  • Ellen K. Ritchie

  • Arati V. Rao

  • M. Isabella Cazacu

  • Shreya Vemuri

  • Martin S. Tallman

  • Dan Douer

  • Jae H. Park

Medical Centers

  • Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Weill Cornell Medical College, Hematology and Medical Oncology, Joan and Sanford I. Weill Department of Medicine, New York, NY

  • Gilead Sciences, Inc., Foster City, CA

  • Leukemia Service, Department of Medicine, New York, NY

  • Sloan Kettering Institute, 1275 York Avenue, NY

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Methotrexate

  • Pegaspargase

  • Oncaspar

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • NCT01920737

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved